MedTrace Logo

Study of the Safety and Efficacy of Dietary Buglossoides Oil

NCT02226354 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-09-02

No results posted yet for this study

Summary

Seeds from the Buglossoides arvensis plant (trademarked as Ahiflower™) produce oil that is a rich natural source (20%) of stearidonic acid (SDA), a metabolic intermediate between omega-3 fatty acids found in other plants (such as flax) and those found in fish oils.

The objectives of this study to collect safety data and to investigate the accumulation of long chain n-3 polyunsaturated fatty acids in human lipids following oral supplementation with Ahiflower oil in healthy adults.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Ahiflower oil

9.73 ml per day for 28 days

DIETARY_SUPPLEMENT

Flaxseed oil

9.73ml per day for 28 days

Sponsors & Collaborators

  • Réseau de Santé Vitalité Health Network

    lead OTHER

Principal Investigators

  • Marc Surette, PhD · Université de Moncton

  • Rémi LeBlanc, MD · Centre Hospitalier Dr Georges-L.-Dumont

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02226354 on ClinicalTrials.gov